12:00 AM
Feb 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ChimeriVax-Dengue: Phase IIb started

sanofi's sanofi pasteur S.A. vaccines unit began a Taiwanese Phase IIb trial (Study 209) to evaluate subcutaneous ChimeriVax-Dengue vaccine in 4,000 healthy children ages 4-11....

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >